Clinical Trial: RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited
Brief Summary: The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
Detailed Summary:
Sponsor: Repligen Corporation
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Repligen Corporation
Dates:
Date Received: May 7, 2003
Date Started:
Date Completion:
Last Updated: August 4, 2005
Last Verified: August 2005